^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    CANCER:

    Colorectal Cancer

    Related cancers:
    1d
    Delayed Systemic Therapy Following Destructive Local Treatment of Pulmonary Oligometastases After No Evidence of Disease (NED) in Colorectal Cancer. (clinicaltrials.gov)
    P2, N=22, Recruiting, Shandong Cancer Hospital and Institute | Trial completion date: Nov 2025 --> Nov 2026
    Trial completion date
    1d
    Clinicopathological Characteristics of Colon Cancer in Young Age (clinicaltrials.gov)
    P=N/A, N=1400, Recruiting, Seoul National University Bundang Hospital | Trial completion date: Dec 2025 --> Dec 2026 | Trial primary completion date: Oct 2025 --> Oct 2026
    Trial completion date • Trial primary completion date
    1d
    The Effect of Oral Clostridium Butyricum on the Recurrence After Colonoscopic Resection of Colorectal Adenoma (clinicaltrials.gov)
    P4, N=294, Not yet recruiting, The Affiliated Hospital of Qingdao University | Trial completion date: Oct 2030 --> Apr 2030 | Initiation date: Oct 2025 --> May 2026 | Trial primary completion date: Oct 2029 --> Apr 2030
    Trial completion date • Trial initiation date • Trial primary completion date
    1d
    CHAT-S: Improving Health Insurance Literacy Among Young Adult Cancer Survivors (clinicaltrials.gov)
    P=N/A, N=300, Recruiting, University of Utah | Enrolling by invitation --> Recruiting
    Enrollment status
    1d
    Phase I/II Study of the Anti-Programmed Death Ligand-1 Durvalumab Antibody (MEDI4736) in Combination With Olaparib and/or Cediranib for Advanced Solid Tumors and Advanced or Recurrent Ovarian, Triple Negative Breast, Lung, Prostate and Colorectal Can... (clinicaltrials.gov)
    P1/2, N=268, Active, not recruiting, National Cancer Institute (NCI) | Trial primary completion date: Apr 2026 --> Oct 2027 | Trial completion date: Jul 2026 --> Oct 2027
    Trial completion date • Trial primary completion date • IO biomarker
    |
    EGFR (Epidermal growth factor receptor) • HER-2 (Human epidermal growth factor receptor 2) • BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • PGR (Progesterone receptor) • BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset)
    |
    BRAF V600E • BRCA2 mutation • BRCA1 mutation • EGFR mutation • BRAF V600 • ALK translocation
    |
    Lynparza (olaparib) • Imfinzi (durvalumab) • Recentin (cediranib)
    1d
    TL938 and Trastuzumab for Patients With HER2-positive Metastatic Colorectal Cancer (clinicaltrials.gov)
    P2, N=80, Recruiting, Suzhou Teligene Ltd. | Not yet recruiting --> Recruiting
    Enrollment open
    |
    HER-2 (Human epidermal growth factor receptor 2) • MSI (Microsatellite instability) • RAS (Rat Sarcoma Virus)
    |
    HER-2 positive • MSI-H/dMMR • RAS wild-type • RAS wild-type + HER-2 positive • HER-2 positive + RAS wild-type
    |
    Herceptin (trastuzumab)
    1d
    Study of ZGGS34 in Participants With Advanced Solid Tumors (clinicaltrials.gov)
    P1/2, N=400, Recruiting, Suzhou Zelgen Biopharmaceuticals Co.,Ltd | Not yet recruiting --> Recruiting
    Enrollment open
    |
    HER-2 (Human epidermal growth factor receptor 2) • MSI (Microsatellite instability) • MUC17 (Mucin 17)
    |
    MSI-H/dMMR
    |
    alveltamig (ZG006)
    1d
    Neoadjuvant Radiotherapy for Rectal Adenocarcinoma With Capecitabine Versus TAS-102 (Neo-REACT): A Multi-center, Randomized, Phase III Trial (clinicaltrials.gov)
    P3, N=210, Recruiting, Shandong Cancer Hospital and Institute | Not yet recruiting --> Recruiting
    Enrollment open
    |
    capecitabine • oxaliplatin • Lonsurf (trifluridine/tipiracil)
    1d
    Screening for Prostate Cancer in Older Patients (PLCO Screening Trial) (clinicaltrials.gov)
    P=N/A, N=76685, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Mar 2026 --> Jun 2027
    Trial completion date
    1d
    Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial (clinicaltrials.gov)
    P1, N=51, Active, not recruiting, National Cancer Institute (NCI) | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    CD4 (CD4 Molecule)
    |
    HER-2 positive • HER-2 amplification • HER-2 expression
    |
    Enhertu (fam-trastuzumab deruxtecan-nxki) • ceralasertib (AZD6738)
    1d
    MRD-positive Colorectal Cancer Patients Combined With Personalized Immune Regulation Diagnosis (clinicaltrials.gov)
    P1, N=10, Enrolling by invitation, Second Affiliated Hospital of Wenzhou Medical University | Not yet recruiting --> Enrolling by invitation | Trial primary completion date: Jul 2024 --> Jul 2026
    Enrollment open • Trial primary completion date • Minimal residual disease
    2d
    A Gut Feeling: Metastatic Colorectal Adenocarcinoma With Dirty Necrosis in a Young Adult Without Risk Factors. (PubMed, Cureus)
    Based on imaging and histopathologic findings, the disease was staged as stage IV CRC with hepatic metastasis. This case highlights the aggressive nature of EOCRC, the diagnostic importance of pathologic features such as dirty necrosis in determining tumor origin, and the need to reconsider diagnostic thresholds when younger adults present with gastrointestinal symptoms.
    Journal
    |
    CEACAM5 (CEA Cell Adhesion Molecule 5)